newsfilter
← Latest News
GlobeNewswire·

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Clinical data from May 2024 on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, median duration of response of 13.5 months;